Cytokine Release Syndrome (CRS) is a major concern in CAR-T therapy. How do you approach the grading and management of CRS? Which strategies have you found most effective for reducing the severity of ...

Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer ...

Fortunately those side effects can usually be well managed. CRS: The Most Common Side Effect The most common side effect of CAR T-cell therapy is called cytokine release syndrome (CRS). CRS occurs ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Think of it this way — the human body is a kingdom which is healthy, prosperous and functions peacefully. Every once in a while, invaders from the pat ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

We collected data on demographics; cancer type, stage, duration, and therapies; and autoimmune or inflammatory disease characteristics before and after CAR T-cell therapy. We investigated presence and ...